Department of Allergy and Respiratory Medicine, Tohno-Kousei Hospital, Gifu.
Int J Gen Med. 2012;5:517-24. doi: 10.2147/IJGM.S20833. Epub 2012 Jun 15.
The clinical efficacy of short-acting β(2)-agonists administered before performing daily activities in chronic obstructive pulmonary disease (COPD) is unclear. The aim of this study was to investigate the clinical effect of supplementary inhaled procaterol hydrochloride in patients with COPD.
Thirty outpatients with moderate to severe COPD (Stage II-IV) regularly using inhaled tiotropium bromide alone and with dyspnea during daily activities were enrolled. Subjects self-administered 20 μg of inhaled procaterol before daily activities no more than four times daily. Dyspnea symptom scores, St George's Respiratory Questionnaire (SGRQ) activity domains, impulse oscillometry system parameters, and pulmonary function tests were recorded at the beginning and end of the 2-week study.
At baseline, more than 80% of subjects reported dyspnea when walking up a slope (100.0%), climbing stairs (100.0%), gardening (93.3%), walking on flat ground (90.0%), bathing (86.7%), getting on a bus or train (83.3%), and changing clothes (80.0%). After 2 weeks, subjects with Stage III symptoms had significantly improved dyspnea scores on walking up a slope (P = 0.047), climbing stairs (P = 0.014), gardening (P = 0.034), walking on flat ground (P = 0.006), getting on a bus or train (P = 0.039), and changing clothes (P = 0.045). Both symptom and activity SGRQ domains improved significantly in subjects with Stage III symptoms (P = 0.036 and P = 0.028, respectively). Resistance of small airways and low-frequency reactance area values improved significantly in subjects with Stage III symptoms (P = 0.003 and P = 0.004, respectively). No significant changes were found in pulmonary function tests.
Use of supplementary inhaled procaterol before performing daily activities improved dyspnea symptoms in subjects with Stage III COPD.
在慢性阻塞性肺疾病（COPD）患者中，在进行日常活动前使用短效β2-激动剂的临床疗效尚不清楚。本研究旨在探讨补充吸入盐酸丙卡特罗对 COPD 患者的临床疗效。
30 例中重度 COPD（II-IV 期）患者，单独使用吸入噻托溴铵，且日常活动时呼吸困难，纳入本研究。患者在日常活动前最多每日 4 次自行吸入 20μg 吸入盐酸丙卡特罗。在研究开始和结束时记录呼吸困难症状评分、圣乔治呼吸问卷（SGRQ）活动领域、脉冲振荡系统参数和肺功能检查。
在基线时，超过 80%的患者在爬坡（100.0%）、爬楼梯（100.0%）、园艺（93.3%）、平地行走（90.0%）、洗澡（86.7%）、上公共汽车或火车（83.3%）和换衣服（80.0%）时报告呼吸困难。2 周后，III 期症状患者爬坡时呼吸困难评分明显改善（P = 0.047）、爬楼梯（P = 0.014）、园艺（P = 0.034）、平地行走（P = 0.006）、上公共汽车或火车（P = 0.039）和换衣服（P = 0.045）。III 期症状患者的症状和活动 SGRQ 领域均显著改善（P = 0.036 和 P = 0.028）。III 期症状患者小气道阻力和低频电抗面积值明显改善（P = 0.003 和 P = 0.004）。肺功能检查无明显变化。
在进行日常活动前使用补充吸入盐酸丙卡特罗可改善 III 期 COPD 患者的呼吸困难症状。
